Colorectal Cancer (CRC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 56 12 73 36 29 54 6 42 3 15 37 62 17 71
Colon Cancer 56 12 73 29 54 6 3 15
Colorectal Carcinoma 12 54 15 17 71
Colon Carcinoma 12 54 15 17 71
Colorectal Cancer, Susceptibility to 56 29 6
Carcinoma of Colon 12 29 6
Colonic Adenoma Recurrence, Reduced Risk of 56 6
Colon Cancer, Susceptibility to 56 6
Colon Cancer, Somatic 56 13
Colonic Neoplasms 43 71
Crc 56 73
Colorectal Cancer with Chromosomal Instability, Somatic 56
Colon Cancer, Advanced, Somatic 56
Cancer, Colorectal, Somatic 39
Colorectal Cancer, Somatic 56
Malignant Tumor of Colon 71
Colorectal Carcinomas 15
Colorectal Neoplasms 71
Colorectal Cancers 15
Cancer, Colorectal 39
Colonic Carcinoma 12
Colonic Neoplasm 17
Colon Cancers 15
Cancer, Colon 39



somatic mutation
autosomal dominant


colorectal cancer:
Inheritance autosomal dominant inheritance somatic mutation


External Ids:

OMIM 56 114500
KEGG 36 H00020
ICD9CM 34 153 153.9
SNOMED-CT 67 93761005
ICD10 32 C18 C18.9
UMLS 71 C0007102 C0009375 C0009402 more

Summaries for Colorectal Cancer

PubMed Health : 62 About colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. The name "colorectal cancer" is used to describe bowel cancer that starts in the colon (the large intestine) or the rectum. Cancer of the small intestine is very rare. Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But by no means do all polyps become cancerous – and if a polyp does become cancerous, it takes many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps. Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will depend on various factors, including the stage of the cancer. In early-stage colorectal cancer, the tumor just needs to be surgically removed. In advanced stages, additional treatments may be considered, such as chemotherapy or radiation therapy. In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make it easier to go back to work.

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to lynch syndrome and familial colorectal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colorectal Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Colorectal cancer and MicroRNAs in cancer. The drugs Erythromycin and Orphenadrine have been mentioned in the context of this disorder. Affiliated tissues include colon, rectum and liver, and related phenotypes are renal cell carcinoma and neoplasm of the stomach

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

OMIM : 56 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500)

MedlinePlus : 42 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 50 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

CDC : 3 Colorectal cancer is cancer that occurs in the colon or rectum. Sometimes it is called colon cancer, for short. As the drawing shows, the colon is the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus. Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer. Screening tests can find polyps so they can be removed before turning into cancer. Screening also helps find colorectal cancer at an early stage, when treatment works best.

KEGG : 36 Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).

UniProtKB/Swiss-Prot : 73 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

Wikipedia : 74 Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1563)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 37.4 TP53 PIK3CA NRAS MLH3 MLH1 FLCN
2 familial colorectal cancer 35.8 TP53 PTPRJ MLH1 APC
3 familial adenomatous polyposis 35.2 TP53 MLH1 MCC CTNNB1 AXIN2 APC
4 colon adenocarcinoma 34.9 TP53 PIK3CA MLH1 CTNNB1 BAX APC
5 polyposis syndrome, hereditary mixed, 1 34.9 MLH1 APC
6 mismatch repair cancer syndrome 34.5 MLH1 CTNNB1 APC
7 cowden syndrome 34.5 TP53 PIK3CA MLH3 MLH1 FLCN
8 adenoma 34.5 TP53 PIK3CA MLH1 CTNNB1 AXIN2 APC
9 adenocarcinoma 34.2 TP53 PIK3CA MLH1 FGFR3 CTNNB1 BAX
10 endometrial cancer 34.1 TP53 PIK3CA NRAS MLH3 MLH1 EP300
11 muir-torre syndrome 34.1 TP53 MLH3 MLH1
12 small intestine cancer 34.0 TP53 MLH1 CTNNB1
13 familial adenomatous polyposis 1 33.8 CTNNB1 APC
14 colorectal adenocarcinoma 33.7 TP53 MLH1 CTNNB1 APC
15 colorectal adenoma 33.7 TP53 MLH1 CTNNB1 APC
16 esophageal cancer 33.3 TP53 PIK3CA MLH1 DCC CTNNB1 BAX
17 lung cancer susceptibility 3 33.2 TP53 PIK3CA NRAS FGFR3 CTNNB1 BAX
18 cervical cancer 33.1 TP53 PIK3CA MLH1 FGFR3 CTNNB1 BAX
19 glioblastoma multiforme 33.0 TP53 PIK3CA NRAS MLH1 CTNNB1 BAX
20 gastric adenocarcinoma 32.9 TP53 PIK3CA NRAS MLH1 CTNNB1 BAX
21 rectum adenocarcinoma 32.7 TP53 PIK3CA MLH1
22 medulloblastoma 32.6 TP53 PIK3CA NRAS EP300 CTNNB1 AXIN2
23 thyroid carcinoma 32.5 TP53 PIK3CA NRAS CTNNB1
24 lymphoma, non-hodgkin, familial 32.5 TP53 RAD54B PIK3CA NRAS BAX APC
25 intestinal benign neoplasm 32.5 TP53 PIK3CA MLH1 CTNNB1 AXIN2 APC
26 neuroblastoma 32.5 TP53 PIK3CA NRAS FGFR3 CTNNB1 AXIN2
27 squamous cell carcinoma 32.5 TP53 PIK3CA FGFR3 EP300 CTNNB1
28 sarcoma 32.4 TP53 PIK3CA NRAS FGFR3 EP300 CTNNB1
29 peutz-jeghers syndrome 32.4 TP53 CTNNB1 APC
30 squamous cell carcinoma, head and neck 32.3 TP53 PIK3CA MLH1 FGFR3 CTNNB1 APC
31 li-fraumeni syndrome 32.3 TP53 MLH1 CTNNB1 BAX
32 cholangiocarcinoma 32.3 TP53 PIK3CA CTNNB1 APC
33 hyperplastic polyposis syndrome 32.3 TP53 APC
34 nasopharyngeal carcinoma 32.3 TP53 PIK3CA NRAS CTNNB1 BAX
35 gallbladder cancer 32.3 TP53 PIK3CA MLH1 CTNNB1 APC
36 myeloma, multiple 32.2 TP53 NRAS FGFR3 EP300 CTNNB1
37 brain cancer 32.1 TP53 PIK3CA NRAS CTNNB1 APC
38 bladder urothelial carcinoma 32.1 TP53 PIK3CA NRAS MLH1 FGFR3 CTNNB1
39 pancreatic adenocarcinoma 32.1 TP53 PIK3CA MLH1 CTNNB1 APC
40 obsolete: squamous cell carcinoma of head and neck 32.0 TP53 PIK3CA FGFR3 CTNNB1
41 ovary adenocarcinoma 32.0 TP53 PIK3CA MLH1 CTNNB1 BAX
42 intrahepatic cholangiocarcinoma 31.9 TP53 CTNNB1 APC
43 basal cell carcinoma 31.9 TP53 MLH1 CTNNB1 BAX AXIN2
44 lung squamous cell carcinoma 31.9 TP53 PIK3CA FGFR3 EP300 CTNNB1
45 anal squamous cell carcinoma 31.8 TP53 PIK3CA MLH1 APC
46 renal cell carcinoma, papillary, 1 31.8 TP53 PIK3CA NRAS FLCN FGFR3 CTNNB1
47 colonic benign neoplasm 31.8 TP53 MLH1 CTNNB1 AXIN2 APC
48 uterine carcinosarcoma 31.8 TP53 PIK3CA MLH1 EP300 CTNNB1
49 melanoma, cutaneous malignant 1 31.8 TP53 PIK3CA NRAS MLH1 CTNNB1
50 polyploidy 31.7 TP53 BUB1

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 21)

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectosigmoid Junction Neoplasm
Small Intestine Cancer Splenic Flexure Cancer
Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:

Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Human phenotypes related to Colorectal Cancer:

# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 31 HP:0005584
2 neoplasm of the stomach 31 HP:0006753
3 transitional cell carcinoma of the bladder 31 HP:0006740
4 uterine leiomyosarcoma 31 HP:0002891
5 hereditary nonpolyposis colorectal carcinoma 31 HP:0006716

Symptoms via clinical synopsis from OMIM:

colorectal cancer

Clinical features from OMIM:


UMLS symptoms related to Colorectal Cancer:

nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased ionizing radiation sensitivity GR00232-A-1 9.56 AXIN2 BUB1 EP300 MLH1 NRAS PTPN12
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 APC BUB1 CTNNB1 FGFR3 NRAS
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 BAX EP300 MLH1 MLH3 RAD54B TP53

MGI Mouse Phenotypes related to Colorectal Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 APC AXIN2 BAX BUB1 CTNNB1 DCC
2 homeostasis/metabolism MP:0005376 10.43 APC AXIN2 BAX BUB1 CTNNB1 DLC1
3 hematopoietic system MP:0005397 10.41 APC BAX BUB1 CTNNB1 DCC DLC1
4 growth/size/body region MP:0005378 10.39 APC AXIN2 BAX BUB1 CTNNB1 DLC1
5 mortality/aging MP:0010768 10.39 APC AXIN2 BAX BUB1 CTNNB1 DCC
6 immune system MP:0005387 10.36 APC BAX BUB1 CTNNB1 DCC EP300
7 cardiovascular system MP:0005385 10.34 APC AXIN2 CTNNB1 DLC1 EP300 FLCN
8 embryo MP:0005380 10.31 APC AXIN2 CTNNB1 DLC1 EP300 FLCN
9 endocrine/exocrine gland MP:0005379 10.3 APC AXIN2 BAX BUB1 CTNNB1 EP300
10 neoplasm MP:0002006 10.25 APC BAX BUB1 CTNNB1 DCC EP300
11 digestive/alimentary MP:0005381 10.23 APC AXIN2 CTNNB1 DCC EP300 FGFR3
12 craniofacial MP:0005382 10.19 APC AXIN2 CTNNB1 DLC1 EP300 FGFR3
13 nervous system MP:0003631 10.14 APC AXIN2 BAX CTNNB1 DCC DLC1
14 normal MP:0002873 10.06 APC AXIN2 BUB1 CTNNB1 DLC1 EP300
15 limbs/digits/tail MP:0005371 10.04 APC AXIN2 BAX CTNNB1 FGFR3 NRAS
16 liver/biliary system MP:0005370 10.02 APC BUB1 CTNNB1 NRAS PTPN12 PTPRJ
17 no phenotypic analysis MP:0003012 10.02 AXIN2 BUB1 CTNNB1 FGFR3 NRAS PIK3CA
18 reproductive system MP:0005389 9.9 APC AXIN2 BAX BUB1 CTNNB1 FGFR3
19 pigmentation MP:0001186 9.65 APC CTNNB1 DCC NRAS TP53
20 respiratory system MP:0005388 9.56 BAX CTNNB1 DCC EP300 FGFR3 MLH1
21 vision/eye MP:0005391 9.36 APC AXIN2 BAX CTNNB1 DCC EP300

Drugs & Therapeutics for Colorectal Cancer

PubMed Health treatment related to Colorectal Cancer: 62

Surgery is performed to remove as much of the cancer as possible. In early stages, further treatment may not be needed. If the cancer is at a more advanced stage, further treatments like radiation therapy or chemotherapy are options.

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 950)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
Orphenadrine Approved Phase 4 83-98-7 4601
Methadone Approved Phase 4 76-99-3 4095
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Bethanechol Approved Phase 4 674-38-4 2370
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Bisacodyl Approved Phase 4 603-50-9
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
Glucagon Approved Phase 4 16941-32-5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
15 Apricot Approved Phase 4
Ranibizumab Approved Phase 4 347396-82-1 459903
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
Ferrous fumarate Approved Phase 4 141-01-5
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Acetaminophen Approved Phase 4 103-90-2 1983
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
Remifentanil Approved Phase 4 132875-61-7 60815
Sodium citrate Approved, Investigational Phase 4 68-04-2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
Magnesium oxide Approved Phase 4 1309-48-4 14792
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44 Mosapride Investigational Phase 4 112885-41-3
45 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
46 Serotonin Agents Phase 4
47 Serotonin Receptor Agonists Phase 4
48 Erythromycin Ethylsuccinate Phase 4
49 Erythromycin Estolate Phase 4
50 Erythromycin stearate Phase 4

Interventional clinical trials:

(show top 50) (show all 5600)
# Name Status NCT ID Phase Drugs
1 Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
2 Preoperative Assessment of Colon Tumor: A Prospective, Blinded Study. Unknown status NCT00114829 Phase 4
3 Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
4 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
5 Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
6 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
7 A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
8 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
9 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
10 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
11 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
12 Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
13 NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
14 The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment Unknown status NCT03130634 Phase 4 Silymarin
15 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
16 Assessment of the Participation Rate and the Diagnostic Accuracy of a Colorectal Cancer Screening Program: CT Colonography Versus Flexible Sigmoidoscopy. Evaluation of a New Model Based on Telediagnosis Unknown status NCT01739608 Phase 4
17 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
18 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
19 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
20 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
21 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
22 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
23 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
24 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
25 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
26 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
27 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
28 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
29 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
30 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
31 Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
32 Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
33 Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery Completed NCT00942461 Phase 4
34 Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV Completed NCT00263055 Phase 4 oxaliplatin
35 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4
36 An Open-label Study of the Safety, Tolerability, and Response Rate of Xeloda in Treatment-naïve Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
37 An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
38 Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial Completed NCT00654212 Phase 4
39 Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon Completed NCT02581423 Phase 4 Capecitabine
40 Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates Completed NCT00628147 Phase 4
41 A Multi-Center, Single-Arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
42 The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer Completed NCT00122720 Phase 4 Darbepoetin Alfa
43 Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
44 Study of the Oxidative Stress in Patients With Colorectal Cancer. Open vs Laparoscopic Approach Completed NCT00928928 Phase 4
45 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
46 Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method Completed NCT01607255 Phase 4 Indigo carmine
47 MR Colonography With Fecal Tagging: A Prospective, Randomized Study Completed NCT00114842 Phase 4
48 A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
49 Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX Completed NCT01493713 Phase 4
50 Effectiveness of Colon Capsule Endoscopy as Colorectal Cancer Method of Screening in The Familiar-Risk Population Completed NCT01557101 Phase 4

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Interferon Alfa-2a
Interferon Alfa-2b
interferon alfacon-1
Interferon gamma-1b
Irinotecan hydrochloride
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 29
2 Colorectal Cancer 29
3 Colon Cancer 29
4 Colorectal Cancer, Susceptibility to 29

Anatomical Context for Colorectal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Cancer:

Colon, Rectum

MalaCards organs/tissues related to Colorectal Cancer:

Colon, Liver, Testes, Breast, Lymph Node, Lung, T Cells

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 65230)
# Title Authors PMID Year
Loss-of-function mutations in PPAR gamma associated with human colon cancer. 54 61 56 6
10394368 1999
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 61 56 6
22281684 2012
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 54 56 6
12198537 2002
Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. 56 6
16879199 2006
High frequency of mutations of the PIK3CA gene in human cancers. 56 6
15016963 2004
Microsatellite instability in colorectal cancer-the stable evidence. 54 61 56
20142816 2010
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. 54 61 6
12810952 2003
TP53 loss creates therapeutic vulnerability in colorectal cancer. 61 56
25901683 2015
Multitarget stool DNA testing for colorectal-cancer screening. 61 6
25006736 2014
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. 61 56
24024839 2013
Recurrent R-spondin fusions in colon cancer. 61 56
22895193 2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. 61 56
22722830 2012
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. 61 56
21946539 2011
Germline PKHD1 mutations are protective against colorectal cancer. 61 56
21274727 2011
Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer. 61 56
20522424 2010
Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. 54 61 46
19926638 2010
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. 54 61 46
19734943 2009
Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. 54 61 46
19391107 2009
Deregulated expression of miR-106a predicts survival in human colon cancer patients. 54 61 46
18521848 2008
Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. 54 61 46
17827156 2007
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. 54 6
17060676 2006
CHEK2 I157T associates with familial and sporadic colorectal cancer. 61 6
16816021 2006
Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. 54 61 46
16609010 2006
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 54 6
16015629 2005
Colorectal cancer: mutations in a signalling pathway. 61 56
16094359 2005
EphB receptor activity suppresses colorectal cancer progression. 61 56
15973414 2005
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
Mutation of the PIK3CA gene in ovarian and breast cancer. 54 6
15520168 2004
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 54 6
15342696 2004
Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. 54 56
12637750 2003
Hereditary colorectal cancer. 61 56
12621137 2003
BLM heterozygosity and the risk of colorectal cancer. 61 56
12242432 2002
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. 61 6
12089527 2002
Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. 54 6
11459873 2001
Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. 54 6
11317354 2001
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. 61 6
11017067 2000
Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. 61 6
10667569 2000
Beta-catenin mutations in cell lines established from human colorectal cancers. 54 6
9294210 1997
DNA methylation and genetic instability in colorectal cancer cells. 61 56
9122232 1997
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. 61 6
9065402 1997
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. 54 6
9020077 1997
Lessons from hereditary colorectal cancer. 61 56
8861899 1996
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells. 61 6
7509295 1994
Dominant genes for colorectal cancer are not rare. 61 56
1503398 1992
Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. 54 6
1651563 1991
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. 54 6
1848370 1991
Multiple genetic alterations in distal and proximal colorectal cancer. 61 56
2569552 1989
Concerted nonsyntenic allelic loss in human colorectal carcinoma. 61 56
2841761 1988
Chromosome 5 allele loss at the glucocorticoid receptor locus in human colorectal carcinomas. 61 56
3342039 1988
Dominant inheritance of adenomatous colonic polyps and colorectal cancer. 61 56
4000184 1985